Xeris Biopharma Holdings (XERS) Income towards Parent Company (2020 - 2026)

Xeris Biopharma Holdings' Income towards Parent Company history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Income towards Parent Company rose 124.23% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 126.64% YoY) and the FY2025 annual result came in at $554000.0, up 101.01% from the prior year.
• Income towards Parent Company was $2.2 million for Q1 2026 at Xeris Biopharma Holdings, down from $11.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $11.1 million in Q4 2025 and bottomed at -$33.7 million in Q1 2022.
• A 5-year average of -$12.3 million and a median of -$13.4 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company sank 83.12% — and 2025, when it surged 316.72%.
• Xeris Biopharma Holdings' Income towards Parent Company stood at -$12.9 million in 2022, then dropped by 3.56% to -$13.4 million in 2023, then surged by 61.81% to -$5.1 million in 2024, then jumped by 316.72% to $11.1 million in 2025, then sank by 79.84% to $2.2 million in 2026.
• Business Quant data shows XERS's Income towards Parent Company at $2.2 million in Q1 2026, $11.1 million in Q4 2025, and $621000.0 in Q3 2025.